leadXpro in the News
The July edition of DDNEWS, a journal reporting on latest developments in pharma, biotech and life science has pictured the collaboration between leadXpro and the University of Zurich regarding the generation of Sybodies on its frontpage. The article highlights the close partnership of leadXpro with the University of Zurich and the great potential of the Sybodies as research tools and therapeutic agents.
The CEO of leadXpro was interviewed by the journal European CEO. In the Summer edition of 2018 a number of emerging CEOs from Europe based companies are introduced. Michael Hennig’s interview “Taking the lead” emphasizes facts about the core business of leadXpro, the impact of membrane proteins as drug targets and the key advantages leadXpro’s technologies provide to drug discovery and the creation of differentiating medicines.
About leadXpro AG
leadXpro is a lead discovery company focusing on membrane protein drug targets. We are committed to the application of biophysical and structure-based methods for the discovery and optimization of next generation lead compounds. leadXpro’s technology platform enables structural determination of membrane proteins where classical crystallographic techniques fail, unlocking structure-based drug discovery for challenging targets. We capitalize on the knowledge regarding membrane protein structural biology and facilities of the Paul Scherrer Institute (PSI) with premium access to the synchrotron Swiss Light Source(SLS) and the Free Electron Laser (SwissFEL). Core expertise beyond X-ray include single particle cryo-electron microscopy (cryo-EM). For more information, please visitwww.leadxpro.com
leadXpro is a registered trademark in the EU, Switzerland, US and Canada.
Contact: info (at) leadXpro.com